Last reviewed · How we verify
MCV-A vaccine
MCV-A vaccine stimulates the immune system to produce antibodies and cellular immunity against meningococcal serogroup A polysaccharide capsule.
MCV-A is a meningococcal conjugate vaccine that stimulates the immune system to produce antibodies against serogroup A Neisseria meningitidis. Used for Prevention of meningococcal meningitis and septicemia caused by Neisseria meningitidis serogroup A.
At a glance
| Generic name | MCV-A vaccine |
|---|---|
| Sponsor | International Vaccine Institute |
| Drug class | Meningococcal conjugate vaccine |
| Target | Meningococcal serogroup A capsular polysaccharide |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains meningococcal serogroup A capsular polysaccharide conjugated to a protein carrier, which enhances immunogenicity and T-cell dependent responses. This triggers both humoral and cell-mediated immunity to prevent invasive meningococcal disease caused by serogroup A strains. The conjugate formulation improves immunological memory and provides longer-lasting protection compared to unconjugated polysaccharide vaccines.
Approved indications
- Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup A
Common side effects
- Injection site pain or erythema
- Fever
- Myalgia
- Headache
Key clinical trials
- Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, Malawi (PHASE3)
- Evaluation of Typhoid Conjugate Vaccine Effectiveness in Ghana (PHASE4)
- The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps Vaccine in Junior High School Students (PHASE4)
- The Immune Response of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine (PHASE1, PHASE2)
- Evaluating a Caregiver SMS Reminder Intervention to Reduce Immunization Drop-out in Arua, Uganda (NA)
- 4 Pillars Toolkit for Adolescent Vaccination (NA)
- Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine (PHASE3)
- A Single-center, Open Trials to Evaluate the Safety of Freeze-dried Group ACYW135 Meningococcal Conjugate Vaccine (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |